Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
211 hedge funds and large institutions have $5.7B invested in Momenta Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 85 funds opening new positions, 46 increasing their positions, 64 reducing their positions, and 111 closing their positions.
433% more funds holding in top 10
Funds holding in top 10: 3 → 16 (+13)
97% more call options, than puts
Call options by funds: $140M | Put options by funds: $70.9M
39% more capital invested
Capital invested by funds: $4.11B → $5.7B (+$1.59B)
11% less funds holding
Funds holding: 237 → 211 (-26)
23% less first-time investments, than exits
New positions opened: 85 | Existing positions closed: 111
28% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
HBK Investments
Dallas,
Texas
|
+$203M |
| 2 |
Millennium Management
New York
|
+$178M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$97.2M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$80.6M |
| 5 |
OP
Omni Partners
London,
United Kingdom
|
+$64.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$205M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$191M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$160M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$157M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$84.2M |
MNTA Hedge Fund Activity: Q3 2020 in Review
211 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2020, worth a combined $5.7B — up 39% from $4.11B a quarter earlier.
Sellers outnumbered buyers: 111 funds closed out of MNTA and 85 opened new positions — a net loss of 26 holders — while 64 trimmed existing stakes and 46 added.
The largest buyer was HBK Investments, opening a new position worth an estimated $203M. The largest seller was T. Rowe Price Associates, cutting an estimated $205M.
- 211 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2020, down from 237 in Q2 2020.
- Funds reported $5.7B of Momenta Pharmaceuticals, Inc. stock for Q3 2020, up 39% quarter-over-quarter.
- 85 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2020 and 111 closed out, a net change of -26 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2020 was HBK Investments, an estimated $203M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q3 2020 was T. Rowe Price Associates, an estimated $205M sold.
Based on aggregated 13F filings for Q3 2020.